Valproic Acid – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 29 Apr 2023 11:46:38 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Valproic Acid – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use https://www.cannabisclinicians.org/2023/04/29/a-narrative-review-of-the-lesser-known-medications-for-treatment-of-restless-legs-syndrome-and-pathogenetic-implications-for-their-use-2/ Sat, 29 Apr 2023 11:46:38 +0000 https://www.cannabisclinicians.org/?p=28476 There are several well-known treatments for Restless Legs Syndrome (RLS), including dopamine agonists (pramipexole, ropinirole, rotigotine), anticonvulsants (gabapentin and its analogs, pregabalin), oral or intravenous iron, opioids and benzodiazepines. However, in clinical practice, treatment is sometimes limited due to incomplete response or side effects and it is necessary to be aware of other treatment options for RLS, which is the purpose of this review. We performed a narrative review detailing all of the lesser known pharmacological treatment literature on RLS. The review purposefully excludes well-established, well-known treatments for RLS which are widely accepted as treatments for RLS in evidence-based reviews. We also have emphasized the pathogenetic implications for RLS of the successful use of these lesser known agents.

The post A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use appeared first on Society of Cannabis Clinicians.

]]> A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use https://www.cannabisclinicians.org/2023/04/22/a-narrative-review-of-the-lesser-known-medications-for-treatment-of-restless-legs-syndrome-and-pathogenetic-implications-for-their-use/ Sat, 22 Apr 2023 12:31:04 +0000 https://www.cannabisclinicians.org/?p=28393 There are several well-known treatments for Restless Legs Syndrome (RLS), including dopamine agonists (pramipexole, ropinirole, rotigotine), anticonvulsants (gabapentin and its analogs, pregabalin), oral or intravenous iron, opioids and benzodiazepines. However, in clinical practice, treatment is sometimes limited due to incomplete response or side effects and it is necessary to be aware of other treatment options for RLS, which is the purpose of this review. We performed a narrative review detailing all of the lesser known pharmacological treatment literature on RLS. The review purposefully excludes well-established, well-known treatments for RLS which are widely accepted as treatments for RLS in evidence-based reviews. We also have emphasized the pathogenetic implications for RLS of the successful use of these lesser known agents.

The post A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use appeared first on Society of Cannabis Clinicians.

]]> Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial https://www.cannabisclinicians.org/2021/08/19/long-term-safety-and-efficacy-of-add-on-cannabidiol-in-patients-with-lennox-gastaut-syndrome-results-of-a-long-term-open-label-extension-trial-2/ Thu, 19 Aug 2021 15:43:31 +0000 https://www.cannabisclinicians.org/?p=24014 Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.

The post Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial appeared first on Society of Cannabis Clinicians.

]]> Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial https://www.cannabisclinicians.org/2021/08/03/long-term-safety-and-efficacy-of-add-on-cannabidiol-in-patients-with-lennox-gastaut-syndrome-results-of-a-long-term-open-label-extension-trial/ Tue, 03 Aug 2021 19:09:09 +0000 https://www.cannabisclinicians.org/?p=23887 Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.

The post Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial appeared first on Society of Cannabis Clinicians.

]]>